Reports Q3 revenue $103.693M, consensus $101.83M. “Our commercial momentum continues with over $100 million in sales this quarter and enables sustained investment in innovation. We are executing to plan – advancing three Phase 3 melanoma trials and multiple mid-stage programs – to deliver transformative outcomes for patients and sustained value for shareholders,” said Bahija Jallal, Chief Executive Officer of Immunocore (IMCR).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Apple upgraded, Comcast downgraded: Wall Street’s top analyst calls
- Immunocore initiated with an Overweight at Wells Fargo
- Immunocore’s Innovative Approach: A New Hope for PRAME-Positive Cancer Treatment
- Immunocore’s Phase 3 Melanoma Study: A Potential Game Changer?
- Immunocore’s Promising Melanoma Study: A Potential Game-Changer